Mitochondria-Targeted Antioxidant Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mitochondria-targeted antioxidants (MTAs) are not stable in conventional pharmaceutical compositions, making them unsuitable for industrial manufacturing and clinical use due to instability in oral or injectable forms, which limits their clinical application.
Innovation Solution
Development of stabilized liquid and solid formulations of MTAs, including compounds like SkQ1 and SkQR1, using solvents such as glycerol and propylene glycol, and stabilizing agents like ascorbic acid, to enhance stability for oral, nasal, intravenous, and injectable administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If MTAs are prepared in conventional pharmaceutical compositions, then they can be administered orally or injectably, but they become unstable and degrade
Solution Approach 1:
The patent introduces a mitochondria-targeting moiety as an intermediary component that couples with the antioxidant agent. This targeting group (such as lipophilic cations like triphenylphosphonium or Skulachev ions) serves as a mediator that directs the MTA to mitochondria while the patent discovers that specific formulations of these targeted compounds achieve stability. The intermediary structure enables both the stability and the targeted delivery function simultaneously.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of the antioxidant agents through coupling with mitochondria-targeting moieties. By changing the molecular parameters (adding lipophilic cations, adjusting chain lengths, modifying aromatic groups), the patent creates derivatives that have improved stability profiles in pharmaceutical compositions while maintaining their antioxidant activity and mitochondrial targeting capability.
2Stability of the object's composition
If MTAs are stored as ethanol stock solutions at -80°C, then they remain stable, but this method is inconvenient and impossible for industrial manufacturing and patient use
Solution Approach 1:
The patent fundamentally changes the storage parameters by developing formulations that are stable at refrigerated or room temperatures rather than requiring -80°C freezing. This involves changing the solvent system from pure ethanol to stabilized pharmaceutical compositions, adjusting concentration parameters, and modifying the chemical structure through mitochondria-targeting coupling to achieve stability under manufacturable and patient-friendly storage conditions.
Solution Approach 2:
The patent applies preliminary action by pre-stabilizing the MTA compounds through chemical modification (coupling with targeting moieties) and formulation development before clinical use. This preliminary stabilization work, done during the drug development phase, eliminates the need for extreme storage conditions later during manufacturing, distribution, and patient administration.
3Ease of operation
If MTAs are formulated for oral administration, then patient compliance improves, but stability in oral formulations is not achieved
Solution Approach 1:
The patent changes the formulation parameters by developing specific oral dosage forms containing the mitochondria-targeted antioxidants. This involves adjusting solubility parameters, using appropriate excipients and carriers, controlling pH, and optimizing the concentration of the MTA compound to achieve stability in the oral formulation environment while maintaining bioavailability and patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized formulations provide effective treatment and prevention of conditions like diabetes, inflammation, septic shock, and coronary heart disease, with improved bioavailability and prolonged shelf-life, ensuring clinical efficacy and practicality.
Implementation Method 1
the formulation also comprises 1 molar equivalent to 200 molar equivalents of an antioxidation agent that reduces the oxidized form of the compound of Formula I
Implementation Method 2
the liquid formulation comprises a compound of Formula I in 10% to 100% glycerol, from about 10% to about 100% glycol, (e.g., 1,2-propylene glycol) or from about 1% to about 100% (absolute) ethanol
Data Source
AI summary
Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.